eGenesis to Present at 44th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- eGenesis, a biotechnology company developing human-compatible engineered organs to address the global organ shortage, today announced that Mike Curtis, Ph.D., Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 3:30 p.m. PT.
About eGenesis
eGenesis is a clinical-stage biotechnology company developing human-compatible engineered organs to address the severe global organ shortage. The Company’s proprietary genome engineering platform enables extensive, multiplex gene edits to remove key biological barriers, add protective human transgenes, and inactivate endogenous retroviruses. EGEN-2784, a genetically engineered porcine kidney, is the Company’s lead program and is currently being evaluated in a multi-patient Expanded Access study at MGH. eGenesis is headquartered in Cambridge, MA. For more information, visit www.egenesisbio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260107902689/en/
Media
Kimberly Ha
eGenesis
[email protected]
Source: eGenesis
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ExchangeRight Announces Full Subscription of $26.95 Million Net-Leased All-Cash 19 DST
- KAGA FEI Expands Its Software-Embedded Bluetooth Low Energy Module Lineup with ES4L15MA1 and EC4L15MA1
- The Hockey Barn Joins NHL STREET as Official Operator to Expand Hockey Access Across Atlanta
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
JPMorganSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share